The fees of the EPO will shortly be increased by about 5%. The EPO compensates the fees for inflation each two years; the period of two years is a compromise between frequent compensation for…
Litigation and EPO Oppositions/Appeals surrounding a controlled-release dosage form of the drug oxycodone, a morphine-like opioid analgesic developed in 1918, has kept Europe's Pharma IP Lawyers busy…
In its decision "Okklusionsvorrichtung" (Aga v. Occlutech), the Federal Court of Justice (FCJ) denied patent infringement by equivalent means since the contested infringing embodiment was disclosed…
Multiple rulings of the CJEU on the SPC Regulation fail to answer questions posed by the national courts, result in greater confusion and give rise to a need for yet more references.IntroductionIn…
In my blog of 10 June 2011 I had reported about the decision by the Landgericht Duesseldorf "Pramipexol" (4a O 277/10) where the Court of first Instance had granted a PI based on an anonymous…
On 10 February 2012 the Spanish Court handed down a judgment where it accepted for the first time the concept of a "springboard" injunction as a remedy aimed at curing acts of infringement carried…
Laboratoires Negma (hereinafter referred to as “Negma”) is the exclusive licensee of European patent No. 0 520 414 which relates to a method for the preparation of diacetylrhein…
In the mid-1990s, the U.S. joined most of the rest of the world by adopting a 20-year patent term for patent applications filed on or after June 5, 1995. However, the U.S. patent system is unique in…
By decision of 11 January 2012 Pfizer was found liable of abuse of dominant position by the Italian Antitrust Authority and ordered to pay 10.6 million euro. My previous posts on this case can be…
On 20 January 2012 the Court of Appeal in England heard the case of Apimed Medical Honey v Brightwake Limited [2012] EWCA Civ 5. Apimed owned European Patent (UK) 1,237,561 (‘the Patent’) for an…
